FDA approves nasal spray for treatment-resistant depression

FDA approves nasal spray for treatment-resistant depression

Hough said patients would receive the treatment two times a week for a month, then every week and then every other week, along with an oral antidepressant.

More than 16 million adults in the United States suffer from depression.

The Federal Food and Drug Administration (FDA) announced it had approved a new nasal spray for the treatment of long term depression. Like the ketamine sold legally for anesthesia, Spravato is a Schedule III controlled substance, along with opioid painkillers, due to the potential for abuse leading to dependence.

The decision comes after an FDA advisory panel recommended approval of the drug, Spravato, which is created to treat depression in patients who have not benefited from two or more antidepressants. While it is a novel antidepressant for people who do not respond to other treatments, it has also raised concerns of potential for its abuse. TRD is classified as a chronic condition which has an ongoing emotional, function, and economic burden on the individual. More recently, some doctors have given ketamine to people with depression without formal FDA approval. A short-term study showed that those who took the drug and an oral antidepressant demonstrated a reduction in depression symptoms at four weeks when compared to those that received a placebo and an oral antidepressant. At least 150 clinics around the US provide treatment with various forms of the drug, which is available as a low-priced generic. The second trial considered in support of the drug was a withdrawal study, and FDA said its division of psychiatry products had not previously considered such a study as one of the primary pieces of evidence for an approval, but added "it is not unreasonable to do so" in its report. According to Johnson & Johnson, at least one-third of USA adults who have MDD also have TRD. To date, the agency has approved only one other medication for treatment-resistant depression, a fixed-dose combination of fluoxetine and olanzapine (Symbyax). A month of treatments - at two sessions per week - is estimated to cost $4,720 to $6,785, the pharmaceutical company said.

For some patients who have searched for a depression treatment for years, the results of ketamine treatment have been profound. Sage Therapeutics (NASDAQ:SAGE), for example, revealed in January that its drug, SAGE-217 met primary and secondary endpoints in a Phase 3 clinical trial to treat postpartum depression.

Tiffany was diagnosed with depression as a child and tried dozens of antidepressants that didn't work for her. Levesque says the effect will wear off after a few weeks depending on the patient.



Related Posts

Shamima Begum's baby son may have died says family's lawyer
Begum, who fled the United Kingdom to join the Islamic State terror group four years ago, gave birth to her son three weeks ago. However, the Home Secretary has revoked her citizenship, setting up a potential legal challenge by her family.

Warren says tech giants have 'too much power,' need breakup
This comes as more people are beginning to look critically at tech companies and their enormous, often unchecked growth. Facebook would face real pressure from Instagram and WhatsApp to improve the user experience and protect our privacy.

2nd HIV patient in 'sustained remission,' physicians say
"As long as Timothy Brown was the only [one], we'd have always wondered if there [was] something unique about it"'. Now, doctors in Europe are reporting a second case of HIV remission after a similar stem cell transplant .

Samsung Names First European Countries To Get The Galaxy S10 5G
The S10 will come with a 6.1-inch screen, the S10 Plus with a 6.4-inch display and the S10e with a 5.8-inch monitor. The Galaxy S10 release date might be March 8th, but you can expect some deliveries to show up a day early.

Passengers hurt as cruise ship tilts under 115 mph gust
The powerful wind, the couple said, caused the boat to tilt for several minutes - sending chairs and glassware flying. The Norwegian Escape cruise ship was hit by 185km/h winds on Sunday, turning the ship sideways onto its port side.

Fitbit unveils affordable smartwatch in bid to eat into Apple domination
If you never own a Fitbit before, this is probably the one you should go for. "We really think of our users as being on Fitbit". The company announced stripped-down versions of the Versa and the Ace that are up to $40 cheaper than their predecessors.

Motorola’s folding phone will bring the glorious return of the external screen
There is no doubt that the Motorola RAZR remake we started hearing about a year ago will materialize. Otherwise, the user will be prompted to "flip open to unlock" using their password or PIN.

First all-female spacewalk planned
NASA astronauts Anne McClain and Christina Koch are scheduled to suit up and head outside the International Space Station . The space agency insisted it was just a coincidence that the date coincides with the last week of Women's History Month .

The last Blockbuster in the world will be in Bend, Oregon
The chain shut down its last corporate-owned stores in 2014, but some franchisees have remained operational in the years since. Soon after, Blockbuster began closing its doors, though some franchise locations tried to stick it out.

SpaceX Crew Dragon heads home from ISS for Atlantic splashdown
A SpaceX rocket had launched the 16-foot-tall capsule from the Kennedy Space Center in Florida Saturday morning. Musk, also co-founder of electric vehicle maker Tesla Inc, will be watching closely.

© 2015 ExpressNewsline. All Rights reserved.